文献速递妇科母胎医学

BRCA1/2突变携带者口服避孕药使用与卵巢癌风险的国际队列研究

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2021-01-22

这项国际回顾性研究评估了3989名BRCA1和2445名BRCA2突变携带者口服避孕药使用特征与卵巢癌风险的关系。多因素分析显示,在BRCA1突变携带者中,口服避孕药使用时间越长,卵巢癌风险降低越明显,且保护作用持久。

要点

  • BRCA1突变携带者中,口服避孕药使用>10年者卵巢癌风险显著降低(HR 0.37)。
  • 使用5-9年者风险也有降低趋势(HR 0.67),但未达统计学显著。
  • 保护作用在停药15年以上仍持续存在。

核心结论

  • 对于BRCA1突变携带者,口服避孕药使用时间越长,卵巢癌风险降低越明显,且保护作用长期持续。

研究设计与样本

  • 国际回顾性队列研究,纳入3989名BRCA1和2445名BRCA2突变携带者数据。
  • 采用年龄依赖加权Cox回归分析,按研究和出生队列分层,并以乳腺癌诊断作为协变量。
  • 为减少生存偏倚,分析在基线问卷前5年进行左截断。

主要发现

  • BRCA1突变携带者中,卵巢癌患者曾使用口服避孕药的比例为58.6%,未患病者为88.9%。
  • BRCA2突变携带者中,卵巢癌患者曾使用口服避孕药的比例为53.5%,未患病者为80.7%。
  • BRCA1和BRCA2突变携带者中,卵巢癌患者的中位使用年限分别为7年和7年,未患病者分别为9年和8年。
  • BRCA1突变携带者使用≥10年且停药<15年者HR为0.24(95%CI 0.14-0.43),停药>15年者HR为0.56(95%CI 0.18-0.59)。

临床怎么用

  • 对于BRCA1突变携带者,可考虑口服避孕药作为降低卵巢癌风险的措施之一,尤其长期使用可能获益更大。
  • BRCA2突变携带者的证据尚不充分,需个体化评估。

局限性

  • BRCA2突变携带者样本量有限,分析结果不明确。
  • 回顾性研究设计可能存在回忆偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in the general population are well established (approximately 50% risk reduction in ovarian cancer), the estimated risk reduction in mutation carriers is much less precise because of potential bias and small sample sizes. In addition, only a few studies on oral contraceptive use have examined the associations of duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer. OBJECTIVE: This study aimed to investigate in more detail the associations of various characteristics of oral contraceptive use and risk of ovarian cancer, to provide healthcare providers and carriers with better risk estimates. STUDY DESIGN: In this international retrospective study, ovarian cancer risk associations were assessed using oral contraceptives data on 3989 BRCA1 and 2445 BRCA2 mutation carriers. Age-dependent-weighted Cox regression analyses were stratified by study and birth cohort and included breast cancer diagnosis as a covariate. To minimize survival bias, analyses were left truncated at 5 years before baseline questionnaire. Separate analyses were conducted for each aspect of oral contraceptive use and in a multivariate analysis, including all these aspects. In addition, the analysis of duration of oral contraceptive use was stratified by recency of use. RESULTS: Oral contraceptives were less often used by mutation carriers who were diagnosed with ovarian cancer (ever use: 58.6% for BRCA1 and 53.5% BRCA2) than by unaffected carriers (ever use: 88.9% for BRCA1 and 80.7% for BRCA2). The median duration of use was 7 years for both BRCA1 and BRCA2 carriers who developed ovarian cancer and 9 and 8 years for unaffected BRCA1 and BRCA2 carriers with ovarian cancer, respectively. For BRCA1 mutation carriers, univariate analyses have shown that both a longer duration of oral contraceptive use and more recent oral contraceptive use were associated with a reduction in the risk of ovarian cancer. However, in multivariate analyses, including duration of use, age at first use, and time since last use, duration of oral contraceptive use proved to be the prominent protective factor (compared with <5 years: 5-9 years [hazard ratio, 0.67; 95% confidence interval, 0.40-1.12]; >10 years [hazard ratio, 0.37; 95% confidence interval, 0.19-0.73]; Ptrend=.008). The inverse association between duration of use and ovarian cancer risk persisted for more than 15 years (duration of ≥10 years; BRCA1 <15 years since last use [hazard ratio, 0.24; 95% confidence interval, 0.14-0.43]; BRCA1 >15 years since last use [hazard ratio, 0.56; 95% confidence interval, 0.18-0.59]). Univariate results for BRCA2 mutation carriers were similar but were inconclusive because of limited sample size. CONCLUSION: For BRCA1 mutation carriers, longer duration of oral contraceptive use is associated with a greater reduction in ovarian cancer risk, and the protection is long term.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Schrijver LH, Antoniou AC, Olsson H, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol. 2021. PMID: 33493488. doi:10.1016/j.ajog.2021.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。